Announcements Trials
Browse Landscape

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER_GOV 1OTHER 1

Study Type

Interventional 116Observational 5Expanded_access 2

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 5Recurrence 3

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Observational × pomalidomide × Clear all
NCT06163040 2025-07-31

A Study to Evaluate the Safety of EmplicitiĀ® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Bristol-Myers Squibb

Completed
7 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT04458831 2025-06-27

IONA-MM

Sanofi

Active not recruiting
583 enrolled
Plasma cell

Multiple Myeloma

NCT03288974 2025-04-15

Pomalyst PMS

Celgene

Completed
397 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02555839 2025-03-28

Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice

Celgene

Completed
127 enrolled
Plasma cell

Multiple Myeloma

NCT02164955 2022-10-20

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

Celgene

Completed
775 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚔